Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid.

We have used proteomic fingerprinting to investigate diagnosis of Alzheimer's disease (AD). Samples of lumbar cerebrospinal fluid (CSF) from clinically-diagnosed AD cases (n = 33), age-matched controls (n = 20), and mild cognitive impairment (MCI) patients (n = 10) were used to obtain proteomic profiles, followed by bioinformatic analysis that generated a set of potential biomarkers in CSF samples that could discriminate AD cases from controls. The identity of the biomarker ions was determined using mass spectroscopy. The panel of seven peptide biomarker ions was able to discriminate AD patients from controls with a median accuracy of 95% (sensitivity 85%, specificity 97%). When this model was applied to an independent blind dataset from MCI patients, the intensity of signals was intermediate between the control and AD patients implying that these markers could potentially predict patients with early neurodegenerative disease. The panel were identified, in order of predictive ability, as SPARC-like 1 protein, fibrinogen alpha chain precursor, amyloid-β, apolipoprotein E precursor, serum albumin precursor, keratin type I cytoskeletal 9, and tetranectin. The 7 ion ANN model was further validated using an independent cohort of samples, where the model was able to classify AD cases from controls with median accuracy of 84.5% (sensitivity 93.3%, specificity 75.7%). Validation by immunoassay was performed on the top three identified markers using the discovery samples and an independent sample cohort which was from postmortem confirmed AD patients (n = 17).

[1]  M. Citron,et al.  Parkinson's Disease-associated α-Synuclein Is More Fibrillogenic than β- and γ-Synuclein and Cannot Cross-seed Its Homologs* , 2000, The Journal of Biological Chemistry.

[2]  K. Davis,et al.  The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. , 1983, Psychopharmacology bulletin.

[3]  Margaret A. Pericak-Vance,et al.  Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease , 2006, Neurobiology of Disease.

[4]  M. Sjögren,et al.  Proteome studies of CSF in AD patients , 2006, Mechanisms of Ageing and Development.

[5]  T. Beach,et al.  Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. , 2009, Current Alzheimer research.

[6]  Carol Iversen,et al.  Identification of Enterobacter sakazakii from closely related species: The use of Artificial Neural Networks in the analysis of biochemical and 16S rDNA data , 2006, BMC Microbiology.

[7]  R. Margreiter,et al.  Aberrant tetranectin expression in human breast carcinomas as a predictor of survival , 2004, Journal of Clinical Pathology.

[8]  P. S. St George-Hyslop,et al.  The in Vivo Brain Interactome of the Amyloid Precursor Protein*S , 2008, Molecular & Cellular Proteomics.

[9]  R. Wyatt,et al.  Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia. , 1992, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.

[10]  J. Trojanowski,et al.  Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics , 2007, Nature Reviews Drug Discovery.

[11]  G. Ivy,et al.  Induction of SC1 mRNA Encoding a Brain Extracellular Matrix Glycoprotein Related to SPARC following Lesioning of the Adult Rat Forebrain , 2000, Neurochemical Research.

[12]  Graham R. Ball,et al.  Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks, cluster analysis and principal components analysis , 2005, Bioinform..

[13]  Li-Huei Tsai,et al.  Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis , 2010, The Journal of Neuroscience.

[14]  K. Blennow,et al.  Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease , 2008, Neurobiology of Aging.

[15]  G. Ball,et al.  Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model , 2010, PROTEOMICS - Clinical Applications.

[16]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[17]  S. Strickland,et al.  Fibrinogen, a possible key player in Alzheimer’s disease , 2009, Journal of thrombosis and haemostasis : JTH.

[18]  Y. Sun,et al.  Tetranectin and apolipoprotein A‐I in cerebrospinal fluid as potential biomarkers for Parkinson’s disease , 2010, Acta neurologica Scandinavica.

[19]  K. Blennow,et al.  Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. , 2002, Rapid communications in mass spectrometry : RCM.

[20]  K. Suk,et al.  Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases , 2009, Brain Research.

[21]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[22]  G. Siest,et al.  Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry , 1998, FEBS letters.

[23]  Yan Liu,et al.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.

[24]  C. Merril,et al.  "Ultrasensitive" silver stains: their use exemplified in the study of normal human cerebrospinal fluid proteins separated by two-dimensional electrophoresis. , 1984, Clinical chemistry.

[25]  C. Haass.  Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation , 2004 .

[26]  Chengjie Xiong,et al.  Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis , 2011, PloS one.

[27]  Ian O. Ellis,et al.  Current Developments in the Analysis of Proteomic Data: Artificial Neural Network Data Mining Techniques for the Identification of Proteomic Biomarkers Related to Breast Cancer , 2005 .

[28]  S. Strickland,et al.  Fibrinogen and β-Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's Disease , 2010, Neuron.

[29]  S. Hunsucker,et al.  Proteomic analysis of multiple sclerosis cerebrospinal fluid , 2004, Multiple sclerosis.

[30]  C. Laske.  Blood-based biomarkers in Alzheimer disease. , 2011, Archives of neurology.

[31]  E. Umlauf,et al.  The role of proteomics in dementia and Alzheimer’s disease , 2009, Acta Neuropathologica.

[32]  S. Guertin,et al.  Proteomic Profiling of Cerebrospinal Fluid by 8-Plex iTRAQ Reveals Potential Biomarker Candidates of Alzheimer’s Disease , 2009, Clinical Proteomics.

[33]  Norman Relkin,et al.  Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease , 2007, Annals of neurology.

[34]  G. Melacini,et al.  Stoichiometry and affinity of the human serum albumin-Alzheimer's Aβ peptide interactions. , 2011, Biophysical journal.

[35]  G. Li,et al.  An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers , 2002, Bioinform..

[36]  P. Lewczuk,et al.  Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease , 2004, Biological Psychiatry.

[37]  Christophe Lemetre,et al.  An introduction to artificial neural networks in bioinformatics - application to complex microarray and mass spectrometry datasets in cancer studies , 2008, Briefings Bioinform..

[38]  David M Holtzman,et al.  Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[39]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[40]  Tomasz Sobow,et al.  Biochemical markers and risk factors of Alzheimer's disease. , 2005, Current Alzheimer research.

[41]  Qingzhong Liu,et al.  Independent component analysis of Alzheimer's DNA microarray gene expression data , 2009, Molecular Neurodegeneration.

[42]  V. Marchesi,et al.  Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative‐induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[44]  D. Schadendorf,et al.  Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI‐TOF mass spectrometry/bioinformatic approach , 2007, Proteomics. Clinical applications.

[45]  I. Clemmensen,et al.  Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. , 1986, European journal of biochemistry.